Published online Jul 14, 2022. doi: 10.3748/wjg.v28.i26.3150
Peer-review started: October 26, 2021
First decision: April 16, 2022
Revised: April 25, 2022
Accepted: May 22, 2022
Article in press: May 22, 2022
Published online: July 14, 2022
Processing time: 260 Days and 4.9 Hours
As the main component of oral contraceptives (OCs), ethinylestradiol (EE) has been widely applied as a model drug to induce murine intrahepatic cholestasis. The clinical counterpart of EE-induced cholestasis includes women who are taking OCs, sex hormone replacement therapy, and susceptible pregnant women. Taking intrahepatic cholestasis of pregnancy (ICP) as an example, ICP consumes the medical system due to its high-risk fetal burden and the impotency of ursodeoxycholic acid in reducing adverse perinatal outcomes.
To explore the mechanisms and therapeutic strategies of EE-induced cholestasis based on the liver immune microenvironment.
Male C57BL/6J mice or invariant natural killer T (iNKT) cell deficiency (Jα18-/- mice) were administered with EE (10 mg/kg, subcutaneous) for 14 d.
Both Th1 and Th2 cytokines produced by NKT cells increased in the liver skewing toward a Th1 bias. The expression of the chemokine/chemokine receptor Cxcr6/Cxcl16, toll-like receptors, Ras/Rad, and PI3K/Bad signaling was upregulated after EE administration. EE also influenced bile acid synthase Cyp7a1, Cyp8b1, and tight junctions ZO-1 and Occludin, which might be associated with EE-induced cholestasis. iNKT cell deficiency (Jα18-/- mice) robustly alleviated cholestatic liver damage and lowered the expression of the abovementioned signaling pathways.
Hepatic NKT cells play a pathogenic role in EE-induced intrahepatic cholestasis. Our research improves the understanding of intrahepatic cholestasis by revealing the hepatic immune microenvironment and also provides a potential clinical treatment by regulating iNKT cells.
Core Tip: In this study, we observed the production of both Th1 and Th2 cytokines by natural killer T (NKT) cells in the liver after 14 d of exposure to ethinylestradiol-induced cholestasis. The liver immune microenvironment was also skewed toward a Th1 bias mainly contributed by NKT cells. Invariant NKT cell deficiency robustly alleviated cholestatic liver damage and downregulated the associated signaling pathways, highlighting the pathogenic role and therapeutic potential of hepatic NKT cells in cholestatic liver diseases.